Go or no go? Novo awaits call on oral sema
The Danish group tops the list, while Ardelyx could get its first nod for tenapanor, and Xeris gets a second shot with its hypoglycaemia rescue pen.
The Danish group tops the list, while Ardelyx could get its first nod for tenapanor, and Xeris gets a second shot with its hypoglycaemia rescue pen.
